CTLA4 and neoplasm: Dum and colleagues (174) identified and quantified lymphocyte subpopulations in several tumours including Pheo/PGLs by staining CTLA-4 which is an inhibitory immune checkpoint receptor and a negative regulator of anti-tumour T-cell function which could be another promising target for immunotherapy.